CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionFront Row Advisors LLC
Latest Disclosed Ownership134 shares
Latest Disclosed Value $ 6,374
Front Row Advisors LLC ownership in CRSP / CRISPR Therapeutics AG

On May 19, 2026 - Front Row Advisors LLC filed a 13F-HR form disclosing ownership of 134 shares of CRISPR Therapeutics AG (US:CRSP) valued at $6,374 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 134 shares of CRISPR Therapeutics AG. This represents a change in shares of 0.00% during the quarter. The current value of the position is $6,947 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-19 2026-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 134 0 0.00 6 -14.29 0.0022
2026-02-12 2025-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 134 0 0.00 7 -12.50 0.0023
2025-11-17 2025-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 134 18 15.52 9 60.00 0.0029
2025-08-18 2025-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 116 0 0.00 6 66.67 0.0020
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 116 0 0.00 4 -25.00 0.0015
2025-02-12 2024-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 116 0 0.00 5 -20.00 0.0016
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 116 0 0.00 5 -16.67 0.0019
2024-08-16 2024-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 116 0 0.00 6 -14.29 0.0022
2024-05-14 2024-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 116 0 0.00 8 0.00 0.0029
2024-02-15 2023-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 116 -720 -86.12 7 -81.08 0.0033
2023-11-15 2023-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 836 -15,832 -94.98 38 0.0175
2023-08-15 2023-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 16,668 -600 -3.47 1 0.4163
2023-05-23 2023-03-31 13F/A-1 CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 17,268 -180 -1.03 1 0.3746
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 781 -16,667 2 0.8734
2023-02-15 2022-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 17,448 -1,405 -7.45 1 -100.00 0.3661
2022-11-16 2022-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 18,853 -287 -1.50 1,232 5.93 0.6378
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT STOCK H17182108 19,140 -20 -0.10 1,163 -3.33 0.5722
2022-05-11 2022-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 19,160 100 0.52 1,203 -16.69 0.4850
2022-03-09 2021-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 19,060 1,294 7.28 1,444 -27.40 0.5388
2021-11-03 2021-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 17,766 225 1.28 1,989 -2.93 0.8394
2021-08-23 2021-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 17,541 1,043 6.32 2,049 1.94 0.8407
2021-04-28 2021-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT STOCK H17182108 16,498 536 3.36 2,010 -17.76 0.9738
2021-02-25 2020-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 15,962 -195 -1.21 2,444 24.44 1.2524
2020-11-30 2020-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 16,157 -410 -2.47 1,964 61.25 1.0392
2020-08-17 2020-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 16,567 -205 -1.22 1,218 47.64 0.7553
2020-05-08 2020-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 16,772 16,722 33,444.00 825 27,400.00 0.5575
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 50 0 0.00 3 50.00 0.0020
2019-11-08 2019-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 50 0 0.00 2 0.00 0.0014
2019-08-27 2019-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 50 0 0.00 2 0.00 0.0015
2019-05-17 2019-03-31 13F/A-1 CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 50 50 2 0.0016
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.